Skip to main content

Table 1 Demographic and visual acuity results according to ETDRS letters and logMAR equivalent of enrolled subjects

From: Suprachoroidal spheroidal mesenchymal stem cell implantation in retinitis pigmentosa: clinical results of 6 months follow-up

No./age (years)/sex/eye

Baseline BCVA (ETDRS letters/logMAR)

1-month BCVA (ETDRS letters/logMAR)

3-month BCVA (ETDRS letters/logMAR)

6-month BCVA (ETDRS letters/logMAR)

1/40/female/right

20/1.3

35/1.0

50/0.7

60/0.5

2/39/male/right

20/1.3

20/1.3

20/1.3

20/1.3

3/24/male/left

35/1.0

60/0.5

65/0.4

65/0.4

4/50/female/right

35/1.0

35/1.0

35/1.0

45/0.8

5/56/male/right

35/1.0

60/0.5

60/0.5

60/0.5

6/10/female/right

35/1.0

45/0.8

45/0.8

45/0.8

7/51/female/left

–/2.0

–/2.0

–/1.7

10/1.5

8/49/female/left

–/3.0

–/2.0

–/1.7

–/1.7

9/32/male/right

65/0.4

70/0.3

75/0.2

75/0.2

10/52/male/left

20/1.30

60/0.5

60/0.5

60/0.5

11/34/female/right

–/2.0

–/2.0

–/2.0

–/2.0

12/34/male/right

–/2.0

20/1.3

20/1.3

20/1.3

13/36/male/right

–/2.0

20/1.3

20/1.3

20/1.3

14/34/male/right

50/0.7

65/0.4

65/0.4

70/0.3

15/35/male/left

50/0.7

60/0.5

65/0.4

75/0.2

  1. BCVA best-corrected visual acuity, ETDRS early treatment for diabetic retinopathy study and logMAR logarithm of minimum angle of resolution